Professor, Department of Oncology, McGill University
Lady Davis Institute for Medical Research
Sir Mortimer B. Davis-Jewish General Hospital
3755 Côte Ste-Catherine Road
Montreal, Quebec H3T 1E2
Tel.: 514-340-8222 ext. 8242
lpanasci [at] hotmail [dot] com (Email)
Expertise: Restatement of Cancer Pharmacology: Improving Anticancer Drugs
Summary of Research Activities
Alkylating agents are one of the major classes of anticancer drugs. My laboratory has been attempting to improve the efficacy (therapeutic index) of alkylating agents in cancer for the past 20 years. In order to do this we have taken two opposite approaches: (a) My laboratory has developed a new alkylating agent with selective killing of glioma (brain tumor) cells. This selective anticancer agent called SarCNU specifically accumulates inside tumor cells that express transporters such as the organic cation transporters. There is an entire class of these transporters which are now being characterized. SarCNU was tested in patients in a Phase I trial at the McGill Translational Research Centre in the Jewish General Hospital. This has resulted in a publication. Currently Phase II trials are ongoing with the drug. (b) My laboratory has determined that DNA repair is a pivotal factor in chlorambucil drug resistance in chronic lymphocytic leukemia. Most recently we have been investigating the activity of RAD51 related homologous recombinational repair. We have demonstrated that this type of repair is important in chlorambucil drug resistance in chronic lymphocytic leukemia and probably in epithelial cancers. We are currently examining the ability of Gleevec, a drug utilized in the treatment of chronic myelogenous leukemia, to decrease chlorambucil drug resistance in chronic lymphocytic leukemia.
Ferrario C, Panasci LC. Docetaxel plus cyclophosphamide in adjuvant breast cancer. J Clin Oncol. 2007 Sep 20;25(27):4327; author reply 4327.
Amrein L, Loignon M, Goulet AC, Dunn M, Jean-Claude B, Aloyz R, Panasci L. Chlorambucil Cytotoxicity in Malignant B Lymphocytes Is Synergistically Increased by 2-(Morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-Mediated Inhibition of DNA Double-Strand Break Repair via Inhibition of DNA- Dependent Protein Kinase. J Pharmacol Exp Ther. 2007 Jun;321(3):848-55. Epub 2007 Mar 9
Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4306-14.
Panasci LC. Effect of tamoxifen after chemotherapy in hormone receptor- positive, node-negative breast cancer. J Clin Oncol. 2006 May 20;24(15):2392
Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 2006 Jun 20;24(18):2773-8. Epub 2006 May 8.